Dentsply Sirona Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Dentsply Sirona has dispersed ownership and a separate independent chair, a useful structure during a demanding restructuring. Gregory Lucier must ensure Daniel Scavilla's return-to-growth agenda does not repeat prior acquisition optimism. We see this as the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Dispersed public shareholders own Dentsply Sirona, with Daniel Scavilla leading management and independent chair Gregory Lucier overseeing the board. Daniel Scavilla leads the enterprise and Gregory Lucier provides board or owner oversight, so formal percentages must be read beside board independence, voting rights and contractual authority. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. A governance premium is earned only when independent oversight reduces agency risk and protects capital through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would tie executive rewards to per-share value, balance-sheet resilience and clearly measured strategic outcomes. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
BlackRock, Fuller and Thaler, Vanguard, AQR and State Street hold substantial positions. Their varied styles increase pressure for cash discipline, but frequent ownership turnover can also favor fast financial actions over patient product repair. We see this as the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The institutional register lists BlackRock, Fuller and Thaler Asset Management, Vanguard Portfolio Management, AQR Capital Management, State Street at 12.6%, 6.4%, 5.9%, 5.3%, 4.7%. These stakes influence elections, liquidity and engagement, but they do not guarantee a common view on strategy or risk. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. Stable institutions can reduce financing uncertainty, but concentration cannot substitute for durable operating results or engaged directors. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Dentsply Sirona | Corporate brand | Dental products and technologies |
| CEREC | Product brand | Chairside digital dentistry |
| Primescan | Product brand | Intraoral scanning |
| DS Core | Platform brand | Connected dental workflow |
| SureSmile | Product brand | Clear aligners |
| Astra Tech Implant System | Product brand | Dental implants |
| MIS Implants | Product brand | Dental implants |
| Wellspect | Business brand | Continence care |
| Cavitron | Product brand | Ultrasonic scaling |
| WaveOne | Product brand | Endodontics |
Portfolio Analysis
CEREC, Primescan, DS Core, implants and consumables form a broad clinical portfolio with credible cross-selling potential. Brand breadth is valuable only when service, software and product quality produce reliable clinician workflows. We see this as the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes Dentsply Sirona, CEREC, Primescan, DS Core, SureSmile, Astra Tech Implant System, MIS Implants, Wellspect, Cavitron and WaveOne. Each identity needs a defined customer promise and economic role, with shared capabilities producing measurable benefits instead of administrative complexity. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. A portfolio premium requires evidence that customer trust, technical know-how or distribution produces stronger retention and margins. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Dentsply Sirona ★ | N/A | $3.68B FY2025 | Diversified dental products and technology company |
| Align Technology | N/A | $4B FY2025 | Clear aligners and digital dentistry competitor |
| Envista | N/A | $3B FY2025 | Dental consumables equipment and implants competitor |
| Straumann | N/A | $3B FY2025 | Implants orthodontics and digital dentistry competitor |
| Henry Schein | N/A | $13B FY2025 | Dental distribution and technology company |
Competitive Analysis
Dentsply Sirona competes across equipment, implants, aligners and consumables against focused peers. Its breadth can support bundled workflows, but specialists often move faster and command clearer customer propositions. We see this as the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is 2025 net sales of $3.68 billion, free cash flow of $104 million and 14025 employees, with further impairment and sales pressure continuing into 2026. We test competitive strength through pricing, retention, market share, unit economics and return on invested capital rather than broad claims about addressable markets. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. A competitive premium should follow sustainable cash economics and reinvestment opportunity, not one favorable period or a temporary shortage. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Sirona Dental Systems | $5.5B | 2016 | Created the current diversified dental company |
| Byte | $1.04B | 2021 | Added direct-to-consumer clear aligners |
| MIS Implants | $375M | 2016 | Expanded implant dentistry |
| OraMetrix | $200M | 2018 | Added digital orthodontics |
| Propel Orthodontics | $131M | 2021 | Expanded orthodontic devices |
Acquisitions Analysis
The Sirona merger created scale, while Byte became the clearest example of poor channel and regulatory underwriting. Future deals should remain small until management proves that existing assets can earn their carrying values. We see this as the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because the 2026 plan eliminates the dividend, prioritizes debt reduction and repurchases, and funds restructuring plus targeted connected-dentistry investment. We expect post-deal scorecards to compare promised economics with retention, margins, cash conversion and financing costs. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. Deal-driven growth warrants a premium only when acquired cash flows exceed financing, integration and opportunity costs under conservative assumptions. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
The 2016 merger promised an integrated dental leader, yet impairments and restructuring reveal incomplete value capture. The current board should publish measurable milestones for working capital, product launches and segment returns. We see this as the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The 2016 merger of Dentsply International and Sirona Dental Systems created the present company in a $5.5 billion stock transaction. Later acquisitions added implants, orthodontic software and Byte's direct-to-consumer aligners. Byte was suspended in 2024 after regulatory review, and repeated impairments show that purchased growth has not consistently met its underwriting. Today's segments, leverage, ownership rights and strategic choices are direct consequences of those structural decisions. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. Structural change creates value only when accountability, focus or cash generation improves after tax, financing and integration costs. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership History
Ownership History Analysis
Ownership shifted from two legacy companies to one dispersed public register, followed by leadership turnover and activist-style capital pressure. We see recovery potential, but credibility must be rebuilt through cash outcomes rather than adjusted targets. We see this as the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is a century-old dental manufacturer transformed by the Sirona merger and later acquisitions, several of which produced impairments and strategic retrenchment. We assign heritage value only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. Historical success informs judgment but cannot be capitalized indefinitely when leadership, technology or industry structure changes. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. Our view is that Dentsply Sirona deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership Explained
Dentsply Sirona operates under this ownership structure: Dispersed public shareholders own Dentsply Sirona, with Daniel Scavilla leading management and independent chair Gregory Lucier overseeing the board. Daniel Scavilla leads the enterprise and Gregory Lucier provides board or owner oversight. We treat voting authority, board composition and incentive design as more informative than a shareholder list alone because they determine who can change strategy, approve transactions and set risk tolerance.The operating model is a diversified dental platform spanning consumables, equipment, digital workflows, implants, orthodontics and continence care. Important commercial identities include Dentsply Sirona, CEREC, Primescan, DS Core, SureSmile, Astra Tech Implant System, MIS Implants, Wellspect, Cavitron and WaveOne. We see value when these businesses share technology, distribution, procurement or customer insight without weakening local accountability. Portfolio breadth deserves a premium only if shared ownership improves retention, margins and reinvestment returns.The latest annual record includes 2025 net sales of $3.68 billion, free cash flow of $104 million and 14025 employees, with further impairment and sales pressure continuing into 2026. We use the annual period as the clean scale reference and then incorporate current 2026 developments where they alter ownership, governance or earnings power. Quarterly results can still be distorted by seasonality, transaction timing, launch costs, restructuring charges or volatile end markets.The 2026 plan eliminates the dividend, prioritizes debt reduction and repurchases, and funds restructuring plus targeted connected-dentistry investment. Our view is that capital allocation is the practical expression of ownership. Management and directors should compare each acquisition, repurchase, development program or restructuring decision with debt reduction and retained liquidity, then report whether actual returns matched the original underwriting.
Ownership shapes disclosure, financing flexibility and accountability at Dentsply Sirona. Dispersed public shareholders own Dentsply Sirona, with Daniel Scavilla leading management and independent chair Gregory Lucier overseeing the board. We expect the controlling parties and directors to convert that authority into durable per-share value rather than treating revenue growth, asset count or transaction volume as ends in themselves.The principal downside exposures are weak equipment demand, product quality, regulatory exposure, execution of enterprise systems, recurring impairments, debt and damaged acquisition credibility can suppress returns. We would monitor leading operating indicators that reveal whether the franchise is strengthening before reported earnings fully show the change. Balance-sheet resilience belongs inside ownership analysis because it preserves strategic choice when demand, regulation or capital markets become less favorable.At an August 2026 equity value of $2.24 billion, the market discounts the portfolio heavily and demands evidence that restructuring can restore cash conversion. That benchmark raises the hurdle for new investment and makes scenario discipline essential. We would compare management's implied expectations with conservative cash returns after financing, integration, stock compensation and restructuring costs rather than relying on adjusted profit alone.We would direct most savings to debt and product quality, limit repurchases until cash flow stabilizes, and require board-level postmortems on Byte and other impaired assets. This discipline affects investors, employees, customers, suppliers and creditors because it determines service continuity, employment capacity and financial resilience. We see high-quality ownership only when authority produces transparent decisions, measurable accountability and repeatable cash economics.